CLX Medical, Inc. Announces Status of Validation Study for Zonda, Inc.'s Rapid Point of Care Test for Chlamydia
Published: Jun 17, 2008
MURRIETA, CA--(MARKET WIRE)--Jun 17, 2008 -- CLX Medical, Inc. (OTC BB:CLXN.OB - News), which is focused on the launch and distribution of unique medical diagnostic testing products, today provided an update on the pre-clinical trials validation study for Zonda Incorporated's rapid point of care test for chlamydia. A major purpose of the validation study is to perfect the testing protocol in preparation for the clinical trials as part of the process to achieve FDA clearance for the product.